M&A due diligence · Digital health & life sciences
M&A Privacy & Security Due Diligence for Biotech & Pharma Companies
Privacy and security due diligence for a biotech or pharma company runs in both directions: preparing to be reviewed by a licensing partner or acquirer, and running that same review when the company is the one in-licensing or acquiring an asset. The trigger is a signed term sheet or letter of intent, the moment data findings can still reprice or restructure a deal before it closes. We assess trial data, patient support program vendor contracts, pharmacovigilance history and the protection around unfiled IP — the asset a licensing deal is often actually buying.
Reviewed by the Privacy Horizon team · Last reviewed
What you're protecting
What a biotech or pharma deal's diligence has to examine
A deal in this sector rarely turns on generic IT security findings; it turns on how the three categories of sensitive data have actually been managed.
Trial data ownership and retention posture
Who holds the re-identification key, whether records meet the fifteen-year retention standard, and what obligations transfer to a buyer or partner along with the trial itself.
PSP hub vendor contracts and breach history
What the existing hub-services agreement actually says about security and notification, and whether any past incident at that vendor was disclosed and handled appropriately.
Pharmacovigilance and safety-reporting compliance
Whether adverse-event reporting has consistently met statutory windows, since a pattern of late or missed reporting is both a regulatory and a data-governance red flag.
Protection around unfiled scientific IP
Access controls, confidentiality agreements and technical safeguards around the sequences, processes and dossiers a licensing partner or acquirer is often paying for above everything else.
General corporate and HCP data governance
Employee records, marketing lists and standard corporate systems, reviewed as a baseline indicator of how disciplined the target's overall privacy and security practices actually are.
Regulatory map
The obligations a buyer or partner inherits along with the data
Sensitive data in this sector comes with regulatory obligations attached, and those obligations transfer with the asset whether or not the deal documents mention them.
The fifteen-year trial record-retention clock
A buyer or in-licensing partner inherits the remaining years of the retention obligation on any trial records that transfer, which needs to be reflected in integration planning, not discovered afterward.
PIPEDA accountability moving with ownership
The organization that acquires the data becomes accountable for it under Canadian privacy law, including honouring the terms under which it was originally collected.
US exposure requiring specific disclosure
Whether any part of the target's business has created business associate obligations, versus operating purely on patient authorization or limited data sets, needs to be established clearly before close.
What goes wrong
What undisclosed findings can do to a biotech or pharma deal
The scenarios diligence is built to catch here tend to surface at the worst possible time if they aren't found before signing.
A hub vendor breach history nobody flagged
An incident at a patient support program hub that wasn't properly disclosed or resolved becomes the buyer's problem the moment the deal closes, often with litigation already attached.
Trial data integrity gaps found post-close
Missing or inconsistent records discovered after signing can undermine the value of the trial data itself, and repair costs land entirely on the new owner.
Weak IP protection eroding the actual asset
A licensing or acquisition deal built around unfiled science loses much of its value if diligence reveals the underlying data was never properly access-controlled or contained.
Undisclosed manufacturing or GxP data-integrity risk
Gaps in GMP batch-record controls or manufacturing system security can materially affect the value of a deal involving production assets, and are easy to miss without sector-specific review.
Our m&a due diligence for biotech & pharma companies
What our privacy due diligence covers for a biotech or pharma deal
The same core diligence framework our service always applies, focused specifically on the data categories that actually drive value and risk in this sector.
Risk assessment across trial, PSP and IP data
Identification of data-handling gaps in each of the three categories, framed in terms of deal risk rather than a generic security checklist.
Compliance review against Division 5 and privacy law
An honest read of how the target's actual practices compare to sponsor obligations and Canadian privacy requirements, surfacing what would need remediation.
Diligence packaging for the other side of the table
For a company preparing to be reviewed, documentation of trial, PSP and pharmacovigilance data flows organized in a form a buyer's or partner's team can actually use.
Post-close integration support
Guidance merging privacy and security practices after the deal closes, so the retention obligations, vendor contracts and consent commitments acquired with the data are actually honoured going forward.
How the engagement runs
How privacy due diligence runs for a biotech or pharma deal
Scoped around the three data categories from the outset, whichever side of the deal the company is on.
Step 1
Scope the data categories
We identify what trial data, PSP relationships and IP assets are actually part of the deal, and which regulatory obligations attach to each.
Step 2
Review compliance history and vendor contracts
Past reporting performance, hub and CRO agreements, and any known incidents are examined for what they reveal about ongoing risk.
Step 3
Assess IP protection specifically
Access controls and confidentiality practices around unfiled science are reviewed separately from general IT security, since this is often the deal's actual asset.
Step 4
Report findings in deal-relevant terms
Results are framed around what would need remediation, what should affect price or structure, and what can wait until after close.
Step 5
Support integration after signing
Where the deal closes, we help merge privacy and security practices so obligations acquired with the data are carried forward correctly.
What it costs
What determines privacy due diligence cost for a biotech or pharma deal
Cost depends on deal complexity — the number of active trials, PSP hub relationships and vendor contracts involved — and whether the engagement is preparing the company to be reviewed or reviewing a target or licensing counterparty on the company's behalf.
A single-asset licensing deal with one trial and no PSP costs less to review than an acquisition involving multiple trials, an active patient program and manufacturing operations. We scope pricing once the deal's actual data footprint is understood.
Biotech & Pharma Companies: M&A due diligence questions, answered
Undisclosed breach history at a PSP hub, trial data that cannot support the fifteen-year retention requirement, and weak protection around unfiled IP are the findings most likely to change a deal's price or structure. Findings that are disclosed and quantifiable tend to get priced in; findings discovered after signing tend to trigger disputes instead.
Organize documentation by data category rather than by system: what trial data exists and who holds identifiability, what the PSP hub contract actually commits the vendor to, and what the company's adverse-event reporting track record looks like. A buyer's diligence team moves faster, and trusts the seller more, when the data is already organized this way rather than assembled reactively.
The scope narrows but the rigor doesn't. A licensing deal typically focuses diligence on the specific trial, dataset or IP being licensed, while an acquisition reviews the entire data footprint, but both involve the same underlying questions about ownership, retention and protection of what's changing hands.
Yes, generally. Reviewing your own data practices before a partner's diligence team does gives you time to fix what's fixable and frame what isn't, rather than discovering gaps for the first time in someone else's findings report during active negotiation.
The acquiring organization generally has to honour the terms under which patient data was originally collected, including whatever the PSP's consent language promised about vendor use and data handling. Diligence should confirm those commitments are documented clearly enough for a new owner to actually follow them.
More for biotech & pharma companies
Other services for this niche
About this service
What's Protecting Your Business from the Next Threat?
Don't wait for a breach to expose your vulnerabilities. Let Privacy Horizon secure your data, ensure compliance, and build lasting trust.